» Articles » PMID: 28134726

Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma

Overview
Specialty Dermatology
Date 2017 Jan 31
PMID 28134726
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Primary oral mucosal melanoma is an extremely rare and aggressive tumor arising from melanocytes located in the mucosal epithelium of the oral cavity. Although malignant melanoma of oral mucosa shares some clinical features with its cutaneous counterpart, it has been associated with a worst prognosis; its etiopathogenesis are still only partially unraveled as there is no influence of UV radiation. It is known that the mitogen-activated protein kinase pathway mediates cellular responses to growth signals and its activation is an important phenomenon in melanoma. The aim of this study was to evaluate NRAS and BRAF genes, both components of mitogen-activated protein kinase molecular pathway, and compare with their protein expression. Point mutations of NRAS (codons 12, 13, and 61) and BRAF (codon 600) were screened by pyrosequencing method, and its results were associated to the protein expression of RAS and BRAF performed by immunohistochemistry. The authors observed mutation in BRAF 600 (3/14), NRAS codons 12 and 13 (2/14), and NRAS codon 61 (2/8). One case showed positive RAS protein expression, but no mutation was observed. Twelve in 14 cases showed positive BRAF protein expression: 3 cases showed BRAF mutation; 2 cases showed NRAS codon 61 mutation; 2 cases showed NRAS codons 12 and 13 mutation but not simultaneously. Although NRAS and BRAF mutation frequency and RAS protein expression are low, BRAF protein expression was intense; probably, NRAS and BRAF mutations are independent events and alternative molecular mechanisms in the primary oral mucosal melanoma tumorigenesis.

Citing Articles

Identification of mutations in canine oral mucosal melanomas by exome sequencing and comparison with human melanomas.

Dagli M, Nagamine M, Ikeda T, da Fonseca I, Kremer F, Seixas F Sci Rep. 2024; 14(1):24174.

PMID: 39406779 PMC: 11480479. DOI: 10.1038/s41598-024-74748-z.


Comparative Analysis of the Effect of the BRAF Inhibitor Dabrafenib in 2D and 3D Cell Culture Models of Human Metastatic Melanoma Cells.

Tovar-Parra D, Zammit-Mangion M In Vivo. 2024; 38(4):1579-1593.

PMID: 38936891 PMC: 11215570. DOI: 10.21873/invivo.13608.


Primary melanoma of the oral cavity: A multi-institutional retrospective analysis in Brazil.

Rodrigues B, Cunha J, Albuquerque D, Chagas W, Freire N, Agostini M Med Oral Patol Oral Cir Bucal. 2020; 26(3):e379-e386.

PMID: 33340079 PMC: 8141310. DOI: 10.4317/medoral.24240.


The mutational landscape of mucosal melanoma.

Nassar K, Tan A Semin Cancer Biol. 2019; 61:139-148.

PMID: 31655118 PMC: 7078020. DOI: 10.1016/j.semcancer.2019.09.013.


Targeting the ERK Signaling Pathway in Melanoma.

Savoia P, Fava P, Casoni F, Cremona O Int J Mol Sci. 2019; 20(6).

PMID: 30934534 PMC: 6472057. DOI: 10.3390/ijms20061483.